A summit Conference on Hepatitis B and Hepatitis C held in October 2010 brought together all the major stakeholders for the first time to analyse new and existing information and engage in targeted discussions in a manner to enable European policy makers and other stakeholders to devise public policies in response to the epidemic of Viral Hepatitis B and C in Europe. The Conference presented scientific data and other evidence to an invited audience to urge the formulation of a European-wide strategy on the communication, prevention and management of Viral Hepatitis as a healthcare priority.
The Conference programme increased the stock of existing knowledge on Hepatitis B and Hepatitis C, providing a necessary first step for policy makers and other stakeholders to respond to the epidemic of HBV and HCV in an evidence-based way.
Link to view speaker presentations
Link to view conference agenda
Link to view conference report
New reports commissioned by the Steering Group and presented at the Conference were:
1) A Survey on Patient Self-Help on Hepatitis B and C (view report), by the European Liver Patients Association (ELPA – www.elpa-info.org), and
2) Migration and Hepatitis B and C (view report), by the International Centre for Migration, Health and Development (ICMHD – www.icmhd.wordpress.com).
Call To Action
The Conference concluded by presenting a Call to Action which urged the EU Member States and on the European Commission to work to:
1. Improve awareness of the threat posed by Hepatitis B and Hepatitis C
2. Integrate prevention programmes for Hepatitis B and Hepatitis C into existing public health frameworks
3. Enhance surveillance for Hepatitis B and Hepatitis C across Europe
4. Support the development and integration of cost-effective technologies and procedures for use in viral hepatitis prevention, control and management, including screening of high risk individuals according to scientific and epidemiological based evidence
5. Ensure universal access to early counselling and treatment for persons infected with Hepatitis B or Hepatitis C
6. Expand research resources for hepatitis B and hepatitis C.
The full text of the Call to Action can be viewed HERE.
Members of the Advisory Group are:
the European Centre for Disease Prevention and Control (http://ecdc.europa.eu)
the Viral Hepatitis Prevention Board (www.vhpb.org)
Conference delegates included representatives of 24 of the 27 EU Member States as well as Egypt, Norway, Switzerland and Turkey, and the World Health Organisation, the European Commission, the European Parliament, the European Medicines Agency, the European Centre for Disease Prevention and Control, the European Monitoring Centre for Drugs and Drug Addition, the World Hepatitis Alliance, the European Association for the Study of the Liver, the European Patients Association, the International Centre for Migration, Health and Development and other leading national and European-level stakeholders and policymakers.
Sponsoring partners to the Hepatitis B and C Summit Conference were Bristol-Myers Squibb, Gilead Sciences International, GlaxoSmithKline, Merck & Co and Janssen.